18 completed, 13 unknown, 9 recruiting, 3 active not recruiting. 14 Phase 2, 9 Phase 1, 7 Not applicable, 4 Phase 3.
Follow GIST: new trials by email Literature Review of GIST trials Research Report on GIST
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line) KQB198, Imatinib (Gleevec) - GIST - Gastrointestinal Stromal Tumor, GIST | Phase 2 | Recruiting | Kumquat Biosciences Inc. | 46 | 2026-06-23 | 2026-08-10 |
| Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients Lenvatinib Capsules - GIST | Phase 1 / Phase 2 | Recruiting | Asan Medical Center | 48 | 2025-10-29 | 2026-04-03 |
| Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors Lutetium Lu 177-Edotreotide, Amino Acid Solution - Somatostatin Receptor Positive, NETs | Phase 1 | Recruiting | ITM Solucin GmbH | 20 | 2025-09-26 | 2026-10-27 |
| RCT of EFTR Versus STER for GIST Treatment Endoscopic full thickness resection (EFTR) / Exposed non-tunneling EFTR, Submucosal Tunneling Endoscopic Resection (STER) / Exposed tunneling EFTR - Small Size Gastrointestinal Stromal Tumors, GIST | Not applicable | Recruiting | Chinese University of Hong Kong | 136 | 2025-02-01 | 2026-02-13 |
| A Study of Olverembatinib in SDH-deficient GIST. Olverembatinib - GIST | Phase 3 | Recruiting | Ascentage Pharma Group Inc. | 40 | 2024-11-11 | 2026-07-23 |
| SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST Bezuclastinib in combination with sunitinib - Gastrointestinal Stromal Tumors, GIST | Phase 2 | Active not recruiting | Sarcoma Alliance for Research through Collaboration | 40 | 2024-08-01 | 2025-10-31 |
| A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib Ripretinib, Sunitinib - GIST | Phase 3 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 54 | 2023-12-13 | 2025-12-17 |
| A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies Inlexisertib, Ripretinib - GIST | Phase 1 / Phase 2 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 94 | 2023-09-28 | 2026-10-20 |
| The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study Cancer of Stomach, Oesophageal Cancer | Recruiting | Western Sydney Local Health District | 500 | 2023-03-14 | 2025-03-27 | |
| TARGETed Therapy Drug MONITOring in DIGestive Oncology Blood sampling to build population pharmacokinetics model - Digestive Cancer, Metastatic Colorectal Cancer | Not applicable | Recruiting | UNICANCER | 330 | 2022-08-29 | 2026-08-03 |
| A Drug-drug Interaction Study of Avapritinib and Midazolam Avapritinib, midazolam - Gastrointestinal Stromal Tumors, GIST | Phase 1 | Completed | Blueprint Medicines Corporation | 10 | 2022-08-24 | 2024-12-13 |
| Detective Flow Imaging Endoscopic Ultrasonography in Subepithelial Lesions DFI-EUS, CE-EUS - Leiomyoma, GIST | Not applicable | Unknown | Instituto Ecuatoriano de Enfermedades Digestivas | 30 | 2022-07-20 | 2023-09-28 |
| Liver Transplantation for Unresectable GIST Liver Metastases Liver Transplantation - Liver Diseases, Liver Cancer | Not applicable | Unknown | Hospital Universitario Virgen de la Arrixaca | 50 | 2022-05-01 | 2022-03-11 |
| Exploring the Molecular Mechanism Based on KIT Mutation Imatinib - GIST | Unknown | Xijing Hospital | 190 | 2021-09-10 | 2023-06-09 | |
| French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients Patient treated by Avapritinib in real life - GIST, GIST, Malignant | Unknown | Centre Leon Berard | 25 | 2021-03-31 | 2023-12-26 | |
| Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy Stereotactic radiotherapy - Neuroendocrine Carcinoma of Pancreas, Duodenum Carcinoma | Phase 1 / Phase 2 | Unknown | Erasmus Medical Center | 33 | 2020-12-01 | 2022-12-07 |
| Study in Low Risk Gastrointestinal Stromal Tumor (GISTs) Treatment of Low Risk GISTs according clinical practice (includes drugs, surgery or any other received treatments) - GIST | Completed | Italian Sarcoma Group | 700 | 2020-11-25 | 2024-02-01 | |
| Clinical Evaluation of Genetron D842V PCR Kit in GIST Patients GIST, Gastrointestinal Stromal Tumors | Completed | Genetron Health | 1041 | 2020-11-20 | 2022-06-06 | |
| NIR Fluorescence Imaging With ICG for the Intraoperative Identification of Gastrointestinal Stromal Cell Tumours Intraoperative near-infrared fluorescence imaging using indocyaninegreen - GIST | Phase 2 / Phase 3 | Unknown | Leiden University Medical Center | 10 | 2020-06-17 | 2021-02-18 |
| Long-term Surival of GIST Patients ≥ 10 Years on Imatinib No intervention - GIST | Withdrawn | European Organisation for Research and Treatment of Cancer - EORTC | 2020-06-01 | 2020-09-02 |
Showing 20 of 46. Sign in to see all of them.
Gastrointestinal Stromal Tumors (13) · Carcinoma, Hepatocellular (5) · Carcinoma, Renal Cell (5) · Neoplasm Metastasis (5) · Neuroendocrine Tumors (5) · Pancreatic Neoplasms (5) · Sarcoma (5) · Gastrointestinal Neoplasms (3) · Neoplasms (3) · Stomach Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Transitional Cell (2) · Colonic Neoplasms (2) · Colorectal Neoplasms (2) · Esophageal Neoplasms (2)
Neoplasms (28) · Neoplasms by Histologic Type (27) · Digestive System Diseases (24) · Digestive System Neoplasms (23) · Gastrointestinal Diseases (21) · Neoplasms, Connective and Soft Tissue (20) · Gastrointestinal Neoplasms (18) · Neoplasms by Site (18) · Neoplasms, Connective Tissue (14) · Neoplasms, Glandular and Epithelial (12) · Pathological Conditions, Signs and Symptoms (12) · Adenocarcinoma (9) · Carcinoma (9) · Pathologic Processes (9) · Endocrine Gland Neoplasms (8)
Imatinib Mesylate (5) · Sunitinib (4) · avapritinib (3) · regorafenib (2) · ripretinib (2) · 177Lu-octreotide, DOTA(0)-Tyr(3)- (1) · 6-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine (1) · CHP-HER2 vaccine (1) · Clinical Trials, Phase II as Topic (1) · Coal Tar (1) · Drug Combinations (1) · Endoscopic Mucosal Resection (1) · Endoscopic Ultrasound-Guided Fine Needle Aspiration (1) · Influenza Vaccines (1) · Liver Transplantation (1)
Blueprint Medicines Corporation (3) · Radboud University Medical Center (3) · Centre Leon Berard (2) · Deciphera Pharmaceuticals, LLC (2) · AEterna Zentaris (1) · Adam Burgoyne, MD, PhD (1) · Ariad Pharmaceuticals (1) · Asan Medical Center (1) · Ascentage Pharma Group Inc. (1) · Biogen (1) · Chinese University of Hong Kong (1) · Erasmus Medical Center (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Fox Chase Cancer Center (1) · Genetron Health (1)
United States (19) · France (9) · Netherlands (9) · Spain (7) · China (6) · Italy (5) · Australia (4) · Germany (4) · South Korea (4) · Canada (3) · Poland (3) · United Kingdom (3) · Belgium (2) · Denmark (2) · India (2)
Adam Burgoyne, MD, PhD (1) · Andrew Wagner, MD, PhD (1) · Axel Le Cesne (1) · Brigitte C Widemann, M.D. (1) · Candace Haddox, MD (1) · Carlos Robles-Medranda, MD FASGE (1) · Cesar Serrano, MD (1) · Divyesh V Sejpal, MD (1) · Einat Even-Sapir, MD, PhD (1) · Giovanni Grignani (1) · Hon Chi Yip (1)
PMID 10636102, PMID 11057895, PMID 11215292, PMID 12094370, PMID 12531805, PMID 12538485, PMID 16098458, PMID 16293410, PMID 16550259, PMID 16710031, PMID 17046465, PMID 17435538, PMID 17435539, PMID 18235122, PMID 22661587, PMID 24661373, PMID 25202087, PMID 26416414, PMID 26772734, PMID 27068858, PMID 28448384, PMID 30274985, PMID 34343033, PMID 34965951, PMID 34998048, PMID 37105265, PMID 39229786, PMID 39317507, PMID 40204996, PMID 40579407
2016 (1), 2017 (1)